

Supplementary Material

Table S1. Demographic and clinical profile of the study patients.

Characteristic		Result (n=39)
Age (years); (mean±SD; min-max)		43.95 ± 12.61 (17-73)
Sex; n (%)	Female	28 (71.8)
	Male	11 (28.2)
Tobacco use; n (%)	Never	13 (33.4)
	Former	21 (53.8)
	Current	5 (12.8)
Alcohol use; n (%)	Never	25 (64.1)
	Former	14 (35.9)
Family history; n (%)		1 (2.6)
CLE Subtype; n (%)	<i>Discoid lupus erythematosus</i>	35 (89.7)
	Tumid lupus erythematosus	4 (10.3)
Age at onset (years); (mean±SD; min-max)		40.13 ± 13.47 (11-68)
Duration of the lesions (months); (mean±SD; min-max)		46.33 ± 47.49 (2-180)
Fitzpatrick skin type; n (%)	2	17 (43.6)
	3	11 (28.2)
	4	11 (28.2)
Distribution of CLE lesion locations, all patients (N=39); n (%) ^a	Rest of the face	23 (58.9)
	Scalp	9 (23.0)
	Lips (cutaneous and/or mucosal)	6 (15.3)
	Back/buttocks	6 (15.3)
	Ears	6 (15.3)
	Nose	4 (10.2)
	Chest	3 (7.6)
	V-area neck (frontal)	3 (7.6)
	Arms	3 (7.6)
	Hands	2 (5.1)
Distribution of lesion location by patient; n (%)	<i>DLE patients (n=35):</i>	
	Rest of the face only	12 (34.2)
	Scalp only	7 (20.0)
	Lips only	1 (2.9)
	Lips and rest of the face	4 (11.4)
	Ears and rest of the face	4 (11.4)
	Scalp and rest of the face	2 (5.7)
	<i>LET patients (n=4):</i>	
	Back	3 (75)
	Chest	1 (25)
Topical treatment; n (%)	Topical corticosteroids	30 (76.9)
	Topical calcineurin Inhibitors	27 (69.2)
	Intralesional steroid injection	9 (23.1)
Systemic therapy; n (%)	Hydroxychloroquine	36 (92.3)
	Systemic corticosteroids	10 (25.6)
	Methotrexate	2 (5.1)
	Isotretinoin	2 (5.1)
	Mycophenolate mofetil	1 (2.6)

Table S1. Demographic and clinical profile of the study patients. (continued)

Characteristic	Result (n=39)
ANA positive; n (%)	16 (41.0)
CLASI activity score; (mean±SD; min-max)	5.23 ± 3.44 (0-12)
CLASI damage score; (mean±SD; min-max)	2.52 ± 2.83 (0-10)

SD = Standard deviation; min = minimum; max = maximum; CLE = Cutaneous lupus erythematosus; DLE = Discoid lupus erythematosus; LET = Lupus erythematosus tumidus; ANA = Antinuclear antibody; CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index.

^aLesion locations were determined according to the CLASI classification, except that lip involvement was evaluated separately from the “rest of the face” category.

Table S2. Distribution of dermoscopic images.

	Location ^a	Images, n (%)
Overall distribution of dermoscopic images (n=48)	Rest of the face	22 (45.8) 9(18.7) 6 (12.5)
	Scalp	4 (8.3)
	Lips (cutaneous and/or mucosal)	3 (6.2)
	Ears	2 (4.1)
	Back	1 (2.08)
	Nose	1 (2.08)
	Chest	
	Arms	

^a Lesion locations were determined according to the CLASI classification, except that lip involvement was evaluated separately from the “rest of the face” category.